1. Home
  2. ERAS vs KOPN Comparison

ERAS vs KOPN Comparison

Compare ERAS & KOPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ERAS
  • KOPN
  • Stock Information
  • Founded
  • ERAS 2018
  • KOPN 1984
  • Country
  • ERAS United States
  • KOPN United States
  • Employees
  • ERAS N/A
  • KOPN N/A
  • Industry
  • ERAS Biotechnology: Pharmaceutical Preparations
  • KOPN Semiconductors
  • Sector
  • ERAS Health Care
  • KOPN Technology
  • Exchange
  • ERAS Nasdaq
  • KOPN Nasdaq
  • Market Cap
  • ERAS 439.7M
  • KOPN 424.9M
  • IPO Year
  • ERAS 2021
  • KOPN 1992
  • Fundamental
  • Price
  • ERAS $2.86
  • KOPN $2.43
  • Analyst Decision
  • ERAS Buy
  • KOPN Strong Buy
  • Analyst Count
  • ERAS 6
  • KOPN 3
  • Target Price
  • ERAS $3.50
  • KOPN $4.25
  • AVG Volume (30 Days)
  • ERAS 1.3M
  • KOPN 4.0M
  • Earning Date
  • ERAS 11-12-2025
  • KOPN 11-12-2025
  • Dividend Yield
  • ERAS N/A
  • KOPN N/A
  • EPS Growth
  • ERAS N/A
  • KOPN N/A
  • EPS
  • ERAS N/A
  • KOPN N/A
  • Revenue
  • ERAS N/A
  • KOPN $45,602,295.00
  • Revenue This Year
  • ERAS N/A
  • KOPN $2.28
  • Revenue Next Year
  • ERAS N/A
  • KOPN $29.71
  • P/E Ratio
  • ERAS N/A
  • KOPN N/A
  • Revenue Growth
  • ERAS N/A
  • KOPN 3.02
  • 52 Week Low
  • ERAS $1.01
  • KOPN $0.71
  • 52 Week High
  • ERAS $3.30
  • KOPN $4.16
  • Technical
  • Relative Strength Index (RSI)
  • ERAS 69.19
  • KOPN 33.83
  • Support Level
  • ERAS $2.21
  • KOPN $2.63
  • Resistance Level
  • ERAS $2.90
  • KOPN $3.28
  • Average True Range (ATR)
  • ERAS 0.20
  • KOPN 0.26
  • MACD
  • ERAS 0.04
  • KOPN -0.11
  • Stochastic Oscillator
  • ERAS 96.19
  • KOPN 10.16

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

About KOPN Kopin Corporation

Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.

Share on Social Networks: